Quarterly Updates6 Nov 2025, 02:13 pm
Senores Pharmaceuticals Reports 131% Y-o-Y Growth in Profit After Tax for Q2 & H1 FY26
AI Summary
Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, announced its un-audited financial results for the second quarter and half year ended 30th September 2025. The company reported a revenue of Rs. 162 Crs. and Rs. 300 Crs. for Q2FY26 and H1FY26 respectively, with a Y-o-Y growth of 161% and 166% respectively. The EBITDA and profit after tax also showed significant growth. The regulated markets delivered a strong performance, and the branded generics business witnessed significant growth. The company remains optimistic about further enhancing the cash conversion cycle going forward.
Key Highlights
- Revenue, EBITDA, and profit after tax showed significant Y-o-Y growth for Q2 & H1 FY26.
- Regulated markets delivered a strong performance with 87% Y-o-Y growth in Q2 FY26 and 78% Y-o-Y basis in H1FY26.
- Branded Generics business witnessed significant growth, with revenues growing more than tenfold Y-o-Y in Q2FY26 and 7x in H1FY26.